ArticleGene therapy2001
Enhancement of MSH receptor- and GAL4-mediated gene transfer by switching the nuclear import pathway.
Article in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 39 citations in OpenAlex.
- Long-term labelling and tracing of endodermal cells using a perpetual cycling Gal4-UAS system.Development (Cambridge, England) · 2025Article
- Barriers to Liposomal Gene Delivery: from Application Site to the Target.Iranian journal of pharmaceutical research : IJPR · 2016Review
- Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.Journal of controlled release : official journal of the Controlled Release Society · 2013Review
- Malignant melanoma and melanocortin 1 receptor.Biochemistry. Biokhimiia · 2013Review
- Engineered biological entities for drug delivery and gene therapy protein nanoparticles.Progress in molecular biology and translational science · 2011Review
- Novel modular transporters delivering anticancer drugs and foreign DNA to the nuclei of target cancer cells.Journal of B.U.ON. : official journal of the Balkan Union of Oncology · 2009Review
- Nuclear entry of nonviral vectors.Gene therapy · 2005Review
- Emerging significance of plasmid DNA nuclear import in gene therapy.Advanced drug delivery reviews · 2003Review
- Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems.Gene therapy · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficient nuclear delivery of plasmid DNA represents a major barrier in nonviral gene transfer. One approach has been to use DNA-binding proteins such as GAL4 from yeast as DNA carriers with nuclear targeting properties. We recently showed, however, that GAL4 is inefficient in targeting DNA to the nucleus because its DNA-binding and nuclear targeting activities are mutually exclusive, which relates to the fact that GAL4 nuclear import occurs via a novel pathway. Here, we 'switch' this pathway to a more conventional one by adding a modified poly-lysine to which an optimized nuclear targeting signal, based on that of the SV40 large T-antigen, is linked. We also use a chimeric GAL4-alpha-melanocyte stimulating hormone (MSH) fusion protein to enable gene transfer to cells expressing the MSH receptor. Switching the nuclear import pathway of the transfecting complex significantly enhances receptor-mediated gene transfer through enabling interaction with desired components of the cellular nuclear import machinery. The present study represents the first demonstration that nuclear targeting signals can enhance receptor-mediated gene delivery, the approaches having important relevance to research and clinical applications, such as in generating transgenic or knock-out animals, or in gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.